ABIVAX (EPA:ABVX) | Finanzwire

BRIEF

published on 01/28/2025 at 08:35, 1 year ago

Abivax unveils its financial calendar for 2025

Financial Results Biotechnology Half-yearly Report Financial Calendar Abivax
PRESS RELEASE

published on 01/28/2025 at 08:30, 1 year ago

Abivax Publishes 2025 Financial Calendar
Abivax publishes its 2025 financial calendar, detailing key financial communications throughout the year. The company is focused on developing therapies for chronic inflammatory diseases

Biotechnology Abivax Therapeutics Chronic Inflammatory Diseases 2025 Financial Calendar
BRIEF

published on 01/27/2025 at 18:05, 1 year ago

ABIVAX: Update on shares and voting rights as of December 31, 2024

Share Capital Voting Rights Actions Abivax Financial Transparency
BRIEF

published on 01/23/2025 at 22:10, 1 year ago

Abivax presents seven abstracts on Obefazimod at ECCO 2025

Biotechnology Abivax Obefazimod Ulcerative Colitis ECCO Congress 2025
PRESS RELEASE

published on 01/23/2025 at 22:05, 1 year ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
Abivax announces presentation of seven abstracts for Obefazimod in ulcerative colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Obefazimod Ulcerative Colitis Clinical Trials ECCO
BRIEF

published on 01/09/2025 at 17:40, 1 year ago

Abivax Reaches Key Enrollment Milestone in Phase 3 ABTECT Trial

Abivax Obefazimod Ulcerative Colitis Phase 3 Trial Clinical Results
PRESS RELEASE

published on 01/09/2025 at 17:35, 1 year ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Abivax achieves key milestone in Phase 3 ABTECT trial enrollment with 82% of target participants enrolled for evaluating obefazimod in ulcerative colitis, aiming for NDA submission by H2 2026

Abivax Obefazimod Ulcerative Colitis Phase 3 ABTECT Trial
BRIEF

published on 12/23/2024 at 22:10, 1 year 1 month ago

Abivax Announces Board Resignation

Abivax Obefazimod Board Resignation Truffle Capital Philippe Pouletty
PRESS RELEASE

published on 12/23/2024 at 22:05, 1 year 1 month ago

Abivax Announces a Change to the Composition of its Board of Directors
Abivax announces a change in its Board of Directors composition as Dr. Philippe Pouletty resigns due to new appointment. The company expresses gratitude for his contributions

Board Of Directors Resignation Abivax Therapeutics Dr. Philippe Pouletty
BRIEF

published on 12/18/2024 at 18:05, 1 year 1 month ago

ABIVAX: Share capital and voting rights as of November 30, 2024

Euronext Paris Share Capital Voting Rights Abivax Investment

Published on 01/31/2026 at 03:15, 5 hours 33 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 6 hours 28 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 7 hours 8 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 8 hours 48 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 9 hours 48 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 6 hours 3 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 10 hours 48 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 12 hours 38 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 12 hours 38 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 12 hours 41 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 17:45, 15 hours 3 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 1 day ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 14 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 15 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 15 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News